HeraMed's product is nothing revolutionary, doppler based foetal monitors already exist and have been approved in the past.
ResApp's diagnostic product for children is a very different approval process.
The Global Head of Diagnostics for Roche ($380B Market Cap) Tim Jaeger believes the digital transformation will drive better clinical decisions and diagnosis. They would be all over ResApp.
- Forums
- ASX - By Stock
- A new Beginning...
HeraMed's product is nothing revolutionary, doppler based foetal...
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)